Currently browsing: Community News

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. Why is investing in drugs to treat rare diseases an attractive investment for drug companies? A compendium on CAR-T Cell Therapy from the National Cancer Institute. Methionine restriction may improve […]

Read more

Assorted News from Last Week: The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers. The Research to Accelerate Cures and Equity (RACE) Act led to an increase in required pediatric studies for recently approved cancer therapies within the first year of the act’s implementation, […]

Read more

Assorted News from Last Week: Cancer survivors have increasingly advocated for research into the long-term effects of their treatment.  Read more about that perspective from post doctoral research scientist and long-term childhood leukemia survivor, Victoria J. Forster. Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But new findings suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer. Scientists have identified variants in two genes that are associated with accelerated aging in childhood […]

Read more

Assorted News from Last Week:

Read more

Assorted News from Last Week: Congress approved the fiscal year 2022 omnibus spending package on March 11.  It included great news for the childhood cancer community:  the STAR Act will receive $30M and the Childhood Cancer Data Initiative will receive $50M.   Pediatric cancer mortality and survival has only improved over the past 40 years in the United States (US) but disparities remain. However, there are often various factors that play a role including age, race/ethnicity, cancer site, and economic status, which can change the outcome or treatments of individuals.   In one of the most complicated evacuations likely ever managed from […]

Read more

Assorted news from last week: Steven E. Lipshultz, MD, is senior author on a new study that shows healthier hearts in long-term childhood cancer survivors treated with a new drug, dexrazoxane, to protect their hearts from heart-damaging chemotherapy — even in those treated nearly 20 years ago. Survivors of childhood cancer who became pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study. Their children also didn’t have higher risks of birth defects or other health problems at birth.  However, the study does suggest that these women face [...] Read more

Assorted news from last week: The story of Moonshot4Kids meets the White House Moonshot:  CAC2 Member Janet Demeter (Jack’s Angels) encourages medical research investment into cures for children with cancer at the 2022 Cancer Moonshot announcement event. CAC2 Member, the National Brain Tumor Society (NBTS) launched a new research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments that can target a brain tumor’s DNA damage response network. More than 60% of patients with […]

Read more